The global market for energy-based aesthetic devices will more than triple, from $8.5 billion in 2026 to nearly $29.4 billion by 2036, according to a new report from research firm Market Decipher. That works out to a 13.2% compound annual growth rate over the ten-year window.

The projection rests on a structural shift already visible in treatment rooms: consumers want visible results without downtime, and non-invasive platforms deliver exactly that. Lasers, radiofrequency (RF), intense pulsed light (IPL) and ultrasound have moved from premium add-ons to foundational tools for skin rejuvenation, body contouring, pigmentation correction and skin tightening.

The US leads on cash-pay demand

The United States remains the world's largest market for these devices, per the study, and the drivers are specific: a mature aesthetics industry, broad consumer acceptance of cosmetic treatments, and — critically for equipment vendors — a strong cash-pay healthcare model that insulates aesthetic spending from insurer reimbursement cycles.

Market Decipher forecasts the US segment growing from $2.7 billion in 2026 to $8.9 billion by 2036, a 12.5% CAGR that trails the global figure only slightly. For American spas and medical spas, that gap between global and domestic growth signals where international expansion capital will flow next — and where domestic operators will face more device-equipped competition.

GLP-1 patients become a device demand engine

The report's most striking near-term number concerns a patient demographic that did not exist a few years ago. Users of GLP-1 weight-loss medications such as Wegovy, Zepbound and Ozempic frequently emerge from significant weight loss with loose skin, facial volume loss and other laxity concerns — indications squarely in the wheelhouse of RF, ultrasound and laser platforms.

Market Decipher estimates this cohort alone could represent a $2 billion procedure opportunity by 2030. For treatment menus, that points to bundled protocols positioned explicitly for post-weight-loss contouring and tightening, and for sales teams it means physicians and medspa operators are budgeting for capital equipment against a patient pipeline that is still expanding.

Private equity keeps scaling the buyer side

The study also flags continued private equity investment in medspas and dermatology practices. Roll-up platforms and larger organizations have the balance sheets to purchase advanced technology outright, which expands treatment options, improves patient retention and supports long-term growth. Independent operators should read this as pricing pressure on both equipment acquisition and per-treatment rates, since scaled chains amortize device costs across higher patient volumes.

For procurement teams, the takeaway is straightforward: demand growth of this magnitude will keep device manufacturers competing on platform versatility — combination RF-plus-laser systems, interchangeable handpieces, and subscription-based consumable models — as practices try to serve rejuvenation, contouring and laxity indications from a single footprint.

For treatment providers, the next data point to watch is whether the GLP-1 procedure opportunity materializes on schedule: a confirmed $2 billion post-weight-loss segment by 2030 would validate the report's steepest growth assumptions well before the 2036 horizon.